We are live on ! Find out more
HSTO

Histogen Inc. Common Stock

Delisted

HSTO was delisted on the 4th of October, 2023.

55 hedge funds and large institutions have $56M invested in Histogen Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $3.49M | Put options by funds: $1.11M

21% more capital invested

Capital invested by funds: $46.3M → $56M (+$9.71M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

10% less funds holding

Funds holding: 6155 (-6)

39% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 23

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

Holders
55
Holders Change
-6
Holders Change %
-9.84%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
14
Reduced
23
Closed
14
Calls
$3.49M
Puts
$1.11M
Net Calls
+$2.38M
Net Calls Change
+$1.77M

HSTO Hedge Fund Activity: Q3 2018 in Review

55 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Histogen Inc. Common Stock (HSTO) for Q3 2018, worth a combined $56M — up 21% from $46.3M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of HSTO and 8 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 14 added.

The largest buyer was Artal Group, opening a new position worth an estimated $2.3M. The largest seller was Sofinnova Investments, cutting an estimated $1.47M.

  • 55 institutional investors held Histogen Inc. Common Stock (HSTO) as of Q3 2018, down from 61 in Q2 2018.
  • Funds reported $56M of Histogen Inc. Common Stock stock for Q3 2018, up 21% quarter-over-quarter.
  • 8 funds opened new Histogen Inc. Common Stock positions in Q3 2018 and 14 closed out, a net change of -6 holders.
  • The largest Histogen Inc. Common Stock buyer in Q3 2018 was Artal Group, an estimated $2.3M added.
  • The largest Histogen Inc. Common Stock seller in Q3 2018 was Sofinnova Investments, an estimated $1.47M sold.

Based on aggregated 13F filings for Q3 2018.